Description
RIVAROOT-10
Rivaroxaban 10 mg Tablets
Division: DIABGLYM
Composition
Each film-coated tablet contains:
Rivaroxaban IP — 10 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Film-coated oral tablet
Product Description
RIVAROOT-10 contains Rivaroxaban 10 mg, a direct oral anticoagulant (DOAC) formulated for the prevention of venous thromboembolic disorders and long-term thromboembolic risk reduction. Rivaroxaban is a highly selective direct Factor Xa inhibitor that helps prevent blood clot formation by interrupting the coagulation cascade, thereby reducing the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and recurrent thromboembolic events.
Rivaroxaban 10 mg is widely prescribed in cardiology, orthopedics, vascular medicine, and internal medicine for thromboprophylaxis following hip and knee replacement surgery, prevention of recurrent venous thromboembolism, and selected patients requiring long-term anticoagulation therapy. It provides effective anticoagulation with predictable pharmacokinetics and does not require routine INR monitoring in most patients.
RIVAROOT-10 is particularly beneficial for patients undergoing major orthopedic surgery, individuals with previous venous thromboembolism, patients requiring extended thromboprophylaxis, and those requiring convenient once-daily oral anticoagulant therapy.
Technical Knowledge of Rivaroxaban
Rivaroxaban selectively and directly inhibits Factor Xa, a key enzyme in the coagulation cascade responsible for the conversion of prothrombin to thrombin. By reducing thrombin generation, Rivaroxaban prevents fibrin clot formation and thrombus development without directly affecting platelet function.
Rivaroxaban has rapid oral absorption, predictable anticoagulant activity, and a relatively short onset of action. It provides consistent anticoagulation with fixed dosing regimens and has fewer dietary interactions compared with vitamin K antagonists.
Mechanism of Action
Rivaroxaban directly inhibits Factor Xa, reduces thrombin generation, prevents fibrin clot formation, inhibits thrombus development, and reduces the risk of venous thromboembolic events.
Key Benefits
Effective prevention of deep vein thrombosis
Prevents pulmonary embolism
Reduces the risk of recurrent venous thromboembolism
Provides postoperative thromboprophylaxis
Predictable anticoagulant activity
No routine INR monitoring required in most patients
Convenient once-daily oral dosing
Suitable for extended anticoagulation under medical supervision
Clinical Applications
RIVAROOT-10 is commonly prescribed for prevention of DVT after hip replacement surgery, prevention of DVT after knee replacement surgery, prevention of pulmonary embolism, extended prevention of recurrent DVT and PE, postoperative thromboprophylaxis, and long-term venous thromboembolic prevention.
Facts About Rivaroxaban
Rivaroxaban is one of the most extensively studied direct oral anticoagulants and has strong clinical evidence supporting venous thromboembolism prevention and treatment. The 10 mg strength is widely used for postoperative thromboprophylaxis and extended prevention of recurrent thromboembolic events. Direct Factor Xa inhibition provides effective anticoagulation with a lower burden of monitoring compared with traditional vitamin K antagonists.
Key Facts
Direct oral anticoagulant (DOAC)
Selective Factor Xa inhibitor
Rivaroxaban 10 mg for thromboprophylaxis and VTE prevention
Effective in DVT and PE prevention
Predictable anticoagulant profile with fixed dosing
Evidence-based thromboembolic prevention therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
RIVAROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Orthopedic Franchise, and Vascular Medicine Franchise across India. The increasing prevalence of venous thromboembolism, orthopedic surgeries, cardiovascular disease, and thromboembolic disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose RIVAROOT-10 for PCD Pharma Franchise?
High prescription potential
Strong physician and specialist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Rivaroxaban 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
RIVAROOT-10 from DIABGLYM combines effective anticoagulation, comprehensive thromboembolic protection, evidence-based vascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, orthopedic surgeons, vascular specialists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and advanced Rivaroxaban formulation.